Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
View stock
VS
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
View stock

Stock highlights

Stock comparison highlights
Stock name
AbbVieJohnson & Johnson
Last price
$276.47$261.44
Currency
USD
USD
$489B$630B
78.1130.31
$3.54$8.63
0.280.23
$6.83$5.28
2.50%2.05%
Sector
HealthHealth
Employees
57,000138,200
Ticker
$ABBV$JNJ
Primary listing
NYSENYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $ABBV or $JNJ on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.